We report biochemical, morphological and neuroradiological findings in a 40-year-old woman affected with type I sialidosis. The clinical symptoms, consisting of a cerebellar syndrome, were first noted at the age of 17 years. The macular cherry-red spot was first observed after 23 years of disease. A CT scan performed at 21 years of age showed enlargement of the fourth ventricle. Nuclear magnetic resonance imaging of the brain performed at the age of 40 showed severe atrophy of the cerebellum and pontine region; atrophy of cerebral hemispheres and of the corpus callosum was also observed. We emphasize the prolonged course of illness in this patient, observed over a long period of time. Of particular interest is the neuroradiological study showing our findings both at the beginning of the disease and after 20 years.

Keywords:
Sialidosis, Macular cherry-red spot, Neuraminidase, Sialyloligosaccharides, Nuclear magnetic resonance imaging
1.
Thomas GH, Beaudet AL: Disorders of glycoprotein degradation and structure: α-Mannosidosis, β-mannosidosis, fucosidosis, sialidosis, aspartylglucosaminuria and carbohydrate-deficient glycoprotein syndrome; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 1995, pp 2529–2561.
2.
Beck M, Bender SW, Reiter HL, Otto W, Bassler R, Dancygier H, Gehler J: Neuraminidase deficiency presenting as non-immune hydrops fetalis. Eur J Pediatr 1984;143:135–139.
3.
Maroteaux P, Humbel R, Strecker G, Michalski J-C, Mand R: Un nouveau type de sialidose avec atteinte rénale: la néphrosialidose. 1. Etude clinique, radiologique et nosologique. Arch Fr Pédiatr 1978;35:819–844.
4.
Roth KS, Chan JC, Ghatak NR, Mamunes P, Miller WW, O’Brien J: Acid alpha neuraminidase deficiency: A nephropathic phenotype? Clin Genet 1988;34:185–194.
5.
Hoogeveen AT, Verheijen FW, d’Azzo A, Galjaard H: Genetic heterogeneity in human neuraminidase deficiency. Nature 1980;285:500–502.
6.
d’Azzo A, Andria G, Strisciuglio P, Galjaard H: Galactosialidosis; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 1995, pp 2825–2837.
7.
Galjaard H: Genetic Metabolic Diseases: Early Diagnosis and Prenatal Analysis. Amsterdam, Elsevier North-Holland, 1980.
8.
Blom W, Luteyn JC, Kelholt-Dijkman HH, Huijmans JG, Loonen MC: Thin-layer chromatography in urine as a rapid indication for the diagnosis of lysosomal acid maltase deficiency (Pompe’s disease). Clin Chim Acta 1983;134:221–227.
9.
Guazzi GC, Ghetti B, Bertolino A, Fiore C, Del Vecchio M, Striano S: Epilessia mioclonica giovanile con macchia rosso ciliegia al fondo dell’occhio: I studio genetico e clinico. Folia Neuropsychiatr 1968;11:737–758.
10.
Guazzi GC, Ghetti B, Barbieri F, Cecio A: Myoclonus epilepsy with cherry-red spot in adult: A peculiar form of mucopolysaccaridosis (a genetical, chemical and ultrastructural study). Acta Neurol (Napoli) 1973;38:542–554.
11.
Durand P, Gatti R, Cavalieri S, Borrone C, Tondeur M, Michalski JC, Strecker G: Sialidosis (mucolipidosis I). Helv Paediatr Acta 1977;32:391–400.
12.
O’Brien JS: Neuraminidase deficiency in the cherry red spot-myoclonus syndrome. Biochem Biophys Res Commun 1977;79:1136–1141.
13.
Strecker G, Hondi-Assah T, Fournet B, Spik G, Montreuil J, Maroteaux P, Durand P, Farriaux JP: Structure of the three major sialyl-oligosaccharides excreted in the urine of five patients with three distinct inborn diseases. I. Cell disease and two new types of mucolipidosis. Biochim Biophys Acta 1976;444:349–358.
14.
Rapin I, Goldfisher S, Katzman R, Engel J, O’Brien JS: The cherry-red spot-myoclonus syndrome. Ann Neurol 1978;3:234–242.
15.
Thomas GH, Tipton RE, Ch’ien LT, Reynolds LW, Miller CS: Sialidase (α-N-acetyl neuraminidase) deficiency: The enzyme defect in an adult with macular cherry-red spots and myoclonus without dementia. Clin Genet 1978;13:369–379.
16.
Thomas PK, Abrams D, Swallow D, Stewart G: Sialidosis type I: Cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobilities of some enzymes known to be glycoproteins. J Neurol Neurosurg Psychiatry 1979;42:873–878.
17.
Federico A, Cecio A, Apponi Battini G, Michalski JC, Strecker G, Guazzi GC: Macular cherry-red spot and myoclonus syndrome: Juvenile form of sialidosis, J Neurol Sci 1980;8:157–169.
18.
Franceschetti S, Uziel G, Di Donato S, Caimi L, Avanzini G: Cherry-red spot myoclonus syndrome and alpha neuraminidase deficiency: Neurophysiological, pharmacological and biochemical study in an adult. J Neurol Neurosurg Psychiatry 1980;43:934–940.
19.
Martin JJ: A propos d’une nouvelle observation de ‘cherry-red spot myoclonus syndrome’. Acta Neurol Belg 1980;80:30–36.
20.
Steinmann L, Tharp BR, Dorfman LJ, Forno LS, Sogg RN, Kelts KA, O’Brien JS: Peripheral neuropathy in the cherry-red spot myoclonus syndrome (sialidosis type I). Ann Neurol 1980;7:450–456.
21.
Harzer K, Cantz M, Sewel AC, Dhareshwar SS, Roggendorf W, Heckl RW, Schofer O, Thumler R, Peiffer J, Schlote W: Normomorphic sialidosis in two female adults with severe neurologic diseae and without sialyl oligosaccariduria. Hum Genet 1986;74:209–214.
22.
Till JS, Roach ES, Burton BK: Sialidosis (neuraminidase deficiency) types I and II: Neuroophthalmic manifestations. J Clin Neuroophthalmol 1987;7:40–44.
23.
Bhigjee AI, Seebaran AR, Petesen EM, Bill PL: Sialidosis type I: First report in the Indian population. A clinical, biochemical and electrophysiological study. Clin Neurol Neurosurg 1991;93:115–118.
24.
Louboutin JP, Nogues B, Caillaud C, Elie B: Multimodality evoked potentials and EEG in a case of cherry red spot myoclonus syndrome and α-neuraminidase deficiency (sialidosis type I). Eur Neurol 1995;35:175–177.
25.
Allegranza A, Tredici G, Marmiroli P, Di Donato S, Franceschetti S, Mariani C: Sialidosis type I: Pathological study in an adult. Clin Neuropathol 1989;8:266–271.
26.
Pshezhetsky AV, Richard C, Michaud L, Igdoura S, Wang S, Elsliger MA, Qu J, Leclerc D, Gravel R, Dallaire L, Potier M: Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Nat Genet 1997;15:316–320.
27.
Bonten E, van der Spoel A, Fornerod M, Grossveld G, d’Azzo A: Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev 1996;10:3156–3169.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.